Last $68.87 USD
Change Today -1.00 / -1.43%
Volume 354.1K
KITE On Other Exchanges
As of 2:15 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/15 - $89.21
52 Week Low
07/16/14 - $21.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. The company has strategic research collaboration and license agreement with Amgen Inc. to advance the application of novel chimeric antigen receptor T cell therapies; and collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

36 Employees
Last Reported Date: 12/12/14
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Total Annual Compensation: $210.9K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc. Expands its Agreement with Tel Aviv Sourasky Medical Center to Research and Develop Novel Chimeric Antigen Receptor Approaches for Cancer Immunotherapy

Kite Pharma, Inc. announced that the company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center's Division of Research and Development.

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process

Kite Pharma, Inc. announced presentations on the company's rapid, six-day manufacturing process for the production of Kite's lead product candidate, KTE-C19. The manufacturing technology enables a patient's T cells to be genetically modified using a gammaretroviral vector to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Kite recently announced filing with the FDA an investigational new drug (IND) application to conduct a Phase 1/2 clinical trial of KTE-C19 for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).

Kite Pharma, Inc. Appoints Claudine Prowse as Senior Vice President, Corporate Communications and Investor Relations

Kite Pharma, Inc. announced the appointment of Claudine Prowse, Ph.D., to the newly created position of Senior Vice President, Corporate Communications and Investor Relations (IR). Dr. Prowse will be primarily responsible for driving the company's communication strategy and initiatives. She will report to Ms. Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer. Most recently, Dr. Prowse served as the Vice President of Investor Relations at Biogen Idec.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $68.87 USD -1.00

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies

Industry Analysis


Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at